Triaryl compounds for treatment of PD-L1 diseases

A compound of Formula (Id):

• or a pharmaceutically acceptable salt, prodrug or bioisostere thereof, wherein:
• R1a is OCH3;
• R1b is F;
• R2a and R2b are each independently selected from the group consisting of H, C1-8 alkyl, C1-8 haloalkyl, —Y, —X2—C(O)2Ra, —X2—ORa, —X2—NRaRb, —X2—CONRaRb, —X2—SO2Ra, —X2—SO2NRaRb, —X2—SO3Ra and —X2—Y wherein each X2 is C1-6 alkylene and any C1-8 alkyl or C1-6 alkylene, is optionally further substituted with one or two members independently selected from OH, SO2NH2, CONH2, C(O)NHOH, PO3H2, COO—C1-8 alkyl or CO2H, and each Y is selected from the group consisting of C3-6 cycloalkyl, C4-8 heterocyclyl and 5- to 6-membered heteroaryl, each of which is optionally further substituted with one to four substituents independently selected from the group consisting of oxo, OH, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxy, C1-4 haloalkoxy, C1-4 hydroxyalkoxy, SO2NH2, CONH2, C(O)NHOH, PO3H2, COO—C1-8 alkyl, SO3H and CO2H;
• or R2a and R2b are combined to form a 4- to 10-membered ring or spirocyclic ring, optionally having one or two additional ring vertices selected from O, N or S;
• wherein the ring formed by combining R2a and R2b, is substituted with 0 to 4 substituents independently selected from the group consisting of oxo, C1-8 alkyl, C1-8 haloalkyl, C1-8 hydroxyalkyl, —X3—C(O)2Ra, —X3—ORa, —X3—NRaRb, —X3—CONRaRb, —X3—SO2Ra, —X3—SO2NRaRb, and —X3—SO3Ra;
• wherein X3 is a bond or C1-6 alkylene;
• R3 and R4 are each independently selected from the group consisting of F, Cl, CN, CH3, OCH3, CH2CH3 and CF3;
• A is a member selected from the group consisting of —N(Ra)—, and —C(═O)N(Ra)—;
• Z is selected from the group consisting of:
• i) a monocyclic, bicyclic, or spirocyclic non-aromatic heterocyclic ring, optionally substituted with one or two oxo groups and optionally substituted with up to four Ra and/or Rb;
• ii) a monocyclic 5- or 6-membered heteroaryl ring, optionally substituted with one to three Rc;
• and
• iii) a fused bicyclic heteroaryl ring, optionally substituted with one to three Rc;
• wherein when A is —N(Ra)—, then Z is a fused bicyclic heteroaryl ring optionally substituted with one to three Rc;
• each Ra is independently selected from the group consisting of H, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkylene-CO2H, C1-6 alkylene-SO3H;
• each Rb is independently selected from the group consisting of H, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkylene-CO2H, and C1-6 alkylene-SO3H, each of which is optionally further substituted with one or two members independently selected from OH, SO2NH2, CONH2, C(O)NHOH, PO3H2, COO—C1-8 alkyl and CO2H;
• and Ra and Rb, when attached to the same nitrogen atom, are optionally combined to form a 4- to 8-membered ring or spirocyclic ring, optionally substituted with halogen, OH, SO2NH2, CONH2, C(O)NHOH, PO3H2, COO—C1-8 alkyl or CO2H;
• each Rc is independently selected from the group consisting of H, halogen, CN, C1-6 alkyl, C1-6 haloalkyl, —Y1, —X4—C(O)2Ra, —O—X4—C(O)2Ra, —X4—ORa, —X4—NRaRb, —X4—CONRaRb, —O—X4—CONRaRb, —X4—SO2Ra, —X4—SO2NRaRb, —X4—SO3Ra, and —N(Ra)—X4—C(O)2Ra, wherein each X4 is a bond or C1-6 alkylene, and each Y1 is selected from the group consisting of C3-6 cycloalkyl and C4-8 heterocyclyl;
• and optionally two Rc on adjacent ring vertices are combined to form a fused 5- or 6-membered heterocyclic ring.